Ipsen (IPSEF.PK) said its partner Teijin obtained manufacturing and marketing approval from the Japan's Ministry of Health, Labour and Welfare for Somatuline 60/90/120 mg for s.c. injection (lanreotide acetate). In Japan, Somatuline is indicated for the treatment of growth hormone and IGF-I (somatomedin-C) hypersecretion and related symptoms in acromegaly and pituitary gigantism.
The company noted that Somatuline will be available in a new enhanced presentation with a pre-filled syringe that does not need reconstitution and with a retractable needle that improves safety for caregivers.
For comments and feedback: editorial@rttnews.com